Kevin Ferro

Bio

Mr Ferro is a Managing Director of Vatera Capital LLC. Prior to forming Ferro Capital in 2001, Mr Ferro was the Global Head of Alternative Investment Strategies for Commerzbank AG, one of Germany's largest listed banks, where he managed a series of multi-manager alternative investment programs for the bank and its clients. Prior to Commerzbank, Mr Ferro was responsible for multimanager products at DE Shaw & Co LP (1994-1998). Mr Ferro is the chairman of the board of directors of Arisaph Pharmaceuticals Inc, an emerging drug discovery and design biopharmaceutical company with active development programs to develop differentiated therapies for diabetes, cancer and cardiovascular diseases, and was a member of the board of directors of Kos Pharmaceuticals Inc, a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and marketing proprietary prescription products for the treatment of chronic diseases with a focus on cardiovascular, metabolic and respiratory diseases, until its acquisition by Abbott Laboratories in 2006. Mr Ferro also serves as the Chief Executive Officer and Chief Investment Officer of Oikos Advisors LLC, the advisory firm responsible for the Jaharis family office, and Ferro Capital LLC, an alternative investment advisory firm Mr Ferro has a BA from Harvard University.